Astellas Pharma Inc., of Tokyo, and the University of Texas MD Anderson Cancer Center in Houston, entered a collaboration to research and develop a new treatment for patients with acute myeloid leukemia that grants Astellas an option to firstly negotiate an exclusive, worldwide license at the end of phase Ib, with phase Ia and phase Ib studies to be conducted by MD Anderson.